Imagion Biosystems has announced the successful completion of the renounceable rights issue raising approximately $3.6 million.
Read Imagion Biosystems’ Right Issue raises $3.6 million.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)